News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The inspection concluded with one minor observation in Form 483
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The product will be marketed by Dr. Reddy's Laboratories Inc.
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Subscribe To Our Newsletter & Stay Updated
